ESR1 and ovarian cancer: A study in ovarian cancer showed that ARID1A alterations may also mediate resistance to platinum chemotherapy and estrogen receptor degraders/modulators [35], which further supports our findings that ARID1A deficiency may render patients insensitive to initial chemotherapy and be associated with relapse.